Hugel Aesthetics

Hugel is a South Korea based global aesthetics company founded in 2001, with a presence in approximately 70 countries and vertically integrated research, development, and manufacturing. The company is a leader in injectable and skincare innovation, with its flagship neurotoxin ranked as the number one best-selling product in South Korea for 10 years.

Hugel Aesthetics is the company’s North American division, focused on commercialization and market expansion across the United States, Canada, and Australia. It is establishing a new category in medical aesthetics by bringing the principles of Korean Aesthetics to Western markets, led by its flagship neurotoxin, Letybo® (letibotulinumtoxinA wlbg), and supported by a growing portfolio of differentiated aesthetic products. For more information, visit hugel-aesthetics.com